No Data
No Data
Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) Latest 6.7% Decline Adds to One-year Losses, Institutional Investors May Consider Drastic Measures
Intellia Therapeutics Insiders Sell US$1.5m Of Stock, Possibly Signalling Caution
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Truist Financial Maintains Intellia Therapeutics(NTLA.US) With Buy Rating
Intellia Therapeutics, Inc. (NTLA): Pioneering Gene Editing Solutions for Health Advancements
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Genmab (GMAB) and Xoma (XOMA)
No Data
10baggerbamm : why is anybody even bothering with this woman she's been negative year-to-date she is no conviction she gives price targets pie in the sky and if she really believed in them she would not be selling these companies she's full of shit she made money one year one time everything else has been a disaster
tankeng : yes this woman has problems and arrogant
OhNowGombie : Another quack you mean? Totally out of her gourd too